Blue Shield Of Calif. Push For Cheaper Biosimilars May Disrupt Market

Humira (adalimumab) is a self-injectable treatment for autoimmune disorders. Since January 2023, … [+] lower-cost Humira-referenced biosimilars have been available to patients. (AP Photo/David J. Phillip, File)